Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

Table 2 Summary of measurement approaches for two assessments

	irRC simulating RECIST1.0	irRC simulating RECIST1.1
Number of target lesions	Up to 5 per organ, up to 10 in total	Up to 2 per organ, up to 5 in total
Measurable lesions	≥10 mm in the longest diameter for all lesions	≥10 mm in the longest diameter for all lesions except for lymph nodes
Measurable lesions		≥15 mm in short axis for nodes
Measurement of each lesion	The longest diameter for all target lesions	The longest diameter for non-nodal lesions, short axis for lymph nodes
New lesions	The presence of new lesion does not define progression	Same as irRC simulating RECIST1.0 except:
	The measurements of the new lesion (s) are included in the sum of the measurements	A lymph node has to be ≥15 mm in short axis to be a measurable new lesion and its short axis measurement is included in the sum
	Up to 5 new lesions per organ, up to 10 new lesions in total can be added to measurements	Up to 2 new lesions per organ, up to 5 new lesions in total can be added to the measurements